Internal Medicine, Endocrinology, Diabetes, & Metabolism · New Hyde Park, NY
NPI
1376698159
Since 2007
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
2800 Marcus Ave
New Hyde Park, NY, 11042
Phone (516) 708-2542
Groups this clinician bills Medicare through
Medicare paid, 2024
$2.7M
165,008 services
Medicare patients, 2024
1,771
Average age 76
Drug cost, 2024
$728K
2,659 prescriptions
Company payments, 2025
$662
From 1 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Stuart Weinerman was code J0897 (injection, denosumab, 1 mg), 90,780 times for 891 patients. In total Stuart Weinerman billed 165,008 services in 25 codes, and Medicare paid $2.7M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2013-12-16.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0897 Injection, denosumab, 1 mg | Office | 90,780 | 891 | $20.51 | $1.9M |
| J3111 Injection, romosozumab-aqqg, 1 mg | Office | 67,095 | 52 | $8.53 | $572K |
| 96372 Injection Administration | Office | 1,854 | 927 | $13.26 | $25K |
| 99214 Office E&M - Established | Office | 1,276 | 1,048 | $108.10 | $138K |
| 77080 Standard X-ray | Office | 1,056 | 1,051 | $46.27 | $49K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 876 | 757 | $14.45 | $13K |
| 99213 Office E&M - Established | Office | 445 | 408 | $75.29 | $34K |
| 99204 Office E&M - New | Office | 166 | 166 | $128.83 | $21K |
| 83036 Blood Count | Office | 70 | 55 | $9.52 | $666 |
| 99215 Office E&M - Established | Office | 51 | 45 | $167.35 | $8,535 |
| 99205 Office E&M - New | Office | 34 | 34 | $195.98 | $6,663 |
| 77081 Standard X-ray | Office | 16 | 16 | $37.54 | $601 |
| 95251 Test - Miscellaneous | Office | 15 | 12 | $29.20 | $438 |
| 99222 Hospital E&M - Initial | Facility | 12 | 12 | $117.76 | $1,413 |
| 99203 Office E&M - New | Office | 12 | 12 | $96.07 | $1,153 |
By year: 2022 $1.8M for 110,809 services; 2023 $2.3M for 138,175 services; 2024 $2.7M for 165,008 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 83036 Blood Count | 70 | 55 | $9.52 | $666 |
Medicare prescription drug claims, 2024
In 2024, the drug Stuart Weinerman prescribed most often to Medicare patients was Levothyroxine Sodium, with 524 prescriptions and refills. In total Stuart Weinerman wrote 2,659 Medicare prescriptions that cost $728K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 524 | 1,455 | 147 | $11K |
| Alendronate Sodium Generic | 361 | 940 | 111 | $3,073 |
| Risedronate Sodium Generic | 354 | 1,009 | 131 | $37K |
| Ibandronate Sodium Generic | 187 | 545 | 73 | $7,025 |
| Synthroid Levothyroxine Sodium | 185 | 515 | 53 | $14K |
| Prolia Denosumab | 120 | 720 | 74 | $206K |
| Raloxifene Hcl Generic | 109 | 308 | 32 | $4,974 |
| Metformin Hcl Generic | 65 | 185 | 24 | $511 |
| Ozempic Semaglutide | 45 | 82 | 14 | $77K |
| Risedronate Sodium Dr Risedronate Sodium | 42 | 98 | 14 | $11K |
| Tymlos Abaloparatide | 38 | 45 | Under 11 | $122K |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 36 | 84 | Under 11 | $4,002 |
| Ultra-Fine Mini Pen Needle Pen Needle, Diabetic | 28 | 87 | 16 | $1,629 |
| Testosterone Generic | 27 | 43 | Under 11 | $12K |
| Atorvastatin Calcium Generic | 26 | 78 | Under 11 | $319 |
Brand drugs: 783 claims; generic drugs: 1,778 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Stuart Weinerman $662 (- in general payments such as food, travel and fees and $662 for research) from 1 company. The largest payer was Neurocrine BioSciences, Inc. with $662.
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. NBIX | 2 | $662 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.